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Background: Sclerostin is a secreted Wnt inhibitor produced almost exclusively by osteocytes, which inhibits bone formation. 
Aromatase inhibitors (AIs), which reduce the conversion of steroids to estrogen, are used to treat endocrine-responsive breast 
cancer. As AIs lower estrogen levels, they increase bone turnover and lower bone mass. We analyzed changes in serum sclerostin 
levels in Korean women with breast cancer who were treated with an AI.
Methods: We included postmenopausal women with endocrine-responsive breast cancer (n=90; mean age, 57.7 years) treated 
with an AI, and compared them to healthy premenopausal women (n=36; mean age, 28.0 years). The subjects were randomly as-
signed to take either 5 mg alendronate with 0.5 µg calcitriol (n=46), or placebo (n=44) for 6 months.
Results: Postmenopausal women with breast cancer had significantly higher sclerostin levels compared to those in premenopaus-
al women (27.8±13.6 pmol/L vs. 23.1±4.8 pmol/L, P<0.05). Baseline sclerostin levels positively correlated with either lumbar 
spine or total hip bone mineral density only in postmenopausal women (r=0.218 and r=0.233; P<0.05, respectively). Serum 
sclerostin levels increased by 39.9%±10.2% 6 months after AI use in postmenopausal women; however, no difference was ob-
served between the alendronate and placebo groups (39.9%±10.2% vs. 55.9%±9.13%, P>0.05).
Conclusion: Serum sclerostin levels increased with absolute deficiency of residual estrogens in postmenopausal women with en-
docrine-responsive breast cancer who underwent AI therapy with concurrent bone loss.
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INTRODUCTION
Bone remodeling is a tightly regulated process leading to bal-
anced resorption and formation of skeletal tissue with the coor-
dinated action of osteocytes [1,2]. Sclerostin is a glycoprotein 
secreted by osteocytes and a potent Wnt inhibitor. Sclerostin 
travels through osteocyte canaliculi to the bone surface where 
it binds to the coreceptors lipoprotein receptor-related protein 
(LRP) 5 and LRP 6; thus, it prevents colocalization with Friz-
zled and Wnt proteins, and reduces osteoblastogenesis and 
bone formation [3]. The clinical relevance of sclerostin in bone 
metabolism was initially recognized in patients with scleroste-
osis or van Buchem’s disease with sclerostin mutations, result-
ing in excessive bone formation leading to osteosclerosis [4].
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 Overexpression of normal human SOST alleles (the scleros-
tin gene) in mice results in osteopenia [5]. Mirza et al. [6] 
compared 20 postmenopausal and 20 premenopausal women 
and found that the former had significantly higher serum 
sclerostin levels. Estrogen replacement and intermittent para-
thyroid hormone (PTH) therapy in postmenopausal women 
lead to a significant reduction in sclerostin levels [7,8]. Sever-
al studies have revealed the molecular mechanism of de-
creased sclerostin production by estrogens. Estrogens bind to 
estrogen receptors and interact with the Wnt/β-catenin signal-
ing pathway, which downregulates osteocyte production of 
sclerostin via estrogen receptor-induced prostaglandin E2 [9].
 Aromatase inhibitors (AIs) are used to treat endocrine-re-
sponsive breast cancer by lowering remnant 17β-estradiol (E2) 
or estrione levels to prevent cancer recurrence [10]. This is the 
preferred adjuvant therapy for postmenopausal women with 
estrogen receptor/progesterone receptor-positive breast cancer, 
because it reduces breast cancer recurrence up to 50% com-
pared to tamoxifen [11-13]. AIs affect bone metabolism by in-
creasing bone turnover rates and accelerating bone loss, lead-
ing to increased fracture risk [2,14-16]. Bisphosphonates are 
the preferred treatment for AI-induced bone loss [2], and cal-
citriol, an active metabolite of vitamin D, in combination with 
an AI is effective for inhibiting tumors [10]. In a previous 
study [2], we reported that the combination of alendronate (5 
mg) and calcitriol (0.5 µg) (Maxmarvil, Yuyu Co., Seoul, Ko-
rea) was quite beneficial for preventing the bone loss that oc-
curs with AI administration in patients with endocrine-respon-
sive breast cancer.
 Here, we analyzed serum sclerostin levels in patients with 
endocrine-responsive breast cancer treated with an AI to as-
sess the changes in serum sclerostin levels following treatment 
with alendronate or placebo.
 
METHODS
Study design and subjects
This study was a randomized, placebo-controlled, double-blind 
study performed at a single center. A cross-sectional comparison 
of sclerostin was performed between premenopausal and post-
menopausal women. Changes in sclerostin levels were analyzed 
in 90 endocrine-responsive breast cancer patients during new 
AI administration over 24 weeks. Forty-four patients received 
5 mg alendronate with 0.5 µg calcitriol, calcium, and vitamin 
D, and the remaining 46 patients received only calcium and vi-
tamin D [2].
 The diagnosis of breast cancer and indication for adjuvant 
chemotherapy were made according to the guidelines of the 
National Comprehensive Cancer Network [10]. Patients who 
met the inclusion criteria were reviewed from March 2010 to 
March 2011. Postmenopausal women who were taking an AI 
after breast cancer surgery were included, and the definitions 
of menopause in these patients were as follows: (1) prior bilat-
eral oophorectomy; (2) amenorrhea for ≥12 months in the ab-
sence of tamoxifen, toremifene, or ovarian suppression; and 
(3) follicle-stimulating hormone and E2 levels in the post-
menopausal range.
 Thirty-six healthy premenopausal women were recruited by 
advertisement and served as controls. All subjects were in-
formed of the nature of the study, and consent was obtained 
from each participant. This protocol was approved by the In-
stitutional Review Board of Severance Hospital.
Biochemical measurements
Blood samples were collected in the morning after an overnight 
fast. Routine serum chemistry determinations including calci-
um and phosphate were performed by standard automated 
techniques. Bone turnover markers were measured using the 
following methods: osteocalcin (OCN; by enzyme-linked im-
munosorbent assay [ELISA], CIS Bio International, Gif-sur-
Yvette, France; intra-assay coefficient of variation [CV], <2.0%; 
interassay CV, <5.0%), C-telopeptide of type I collagen (CTx; 
Osteomark, Ostex International, Seattle, WA, USA; intra-assay 
CV, <5.8%; interassay CV, <5.9%), intact PTH (by immuno-
radiometric assay, Biosource, Nivelles Belgium; intra-assay 
CV, 2.7%; interassay CV, <3.5%), and 25-hydroxyvitamin D 
(25[OH]D by D3-radioimmunoassay-coated tube, Biosource; 
intra-assay CV, 11.0%; interassay CV, 12.5%).
 Serum sclerostin concentrations were measured using a hu-
man sclerostin ELISA kit (Biomedica Co., Wien, Austria) ac-
cording to the manufacturer’s instructions. Intraassay and inter-
assay CVs were 4% to 6% and 5% to 7%, respectively. Scleros-
tin measurements are reported in pmol/L, and the lower limit 
of detection was <8.9 pmol/L. Measurements were taken twice 
at intervals of 24 weeks in postmenopausal women with endo-
crine-responsive breast cancer. Sclerostin was measured only 
at baseline in the premenopausal control group.
Assessment of bone mineral density
Bone mineral density (BMD) at the lumbar spine L1 to L4, 
femoral neck, and total hip was measured in all patients by du-
al-energy X-ray absorptiometry (Hologic Delphi A version 
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12.6, Hologic, Waltham, MA, USA). The measurements were 
performed at baseline and after 24 weeks of treatment.
Statistical analysis
Differences in continuous variables between the premenopaus-
al and postmenopausal endocrine-responsive breast cancer 
groups were determined using Student t test. The correlation 
between continuous variables was analyzed by Pearson corre-
lation analysis. Student t test and the paired t test were used to 
compare sclerostin levels and bone turnover markers in the 
postmenopausal breast cancer group. A P<0.05 was considered 
statistically significant. All analyses were performed using 
IBM SPSS version 18.0 (IBM Co., Armonk, NY, USA).
 
RESULTS
Baseline clinical and biochemical characteristics
This study included 90 postmenopausal women who were di-
agnosed with endocrine-responsive breast cancer and 36 
healthy premenopausal control women. The postmenopausal 
women had a mean age of 57.7 years, and the premenopausal 
women had a mean age of 28.0 years (Table 1). Among the 90 
postmenopausal women, nine (10%) were diagnosed with os-
teoporosis.
 Lumbar spine and total hip BMD were lower in postmeno-
pausal women than in premenopausal women (0.92±0.14 g/
cm2 vs. 0.99±0.01 g/cm2; 0.82±0.11 g/cm2 vs. 0.86±0.10 g/
cm2; postmenopausal vs. premenopausal women; P<0.05, re-
spectively) (Table 1). OCN levels were 74.6% higher and CTx 
was 52.0% higher in postmenopausal women than in premeno-
pausal women (P<0.001, respectively) (Table 1). Baseline se-
rum sclerostin levels were 20.3% higher in the postmenopausal 
group compared to those in the premenopausal group (P<0.05) 
(Table 1).
Correlation between sclerostin and bone metabolism
Table 2, Fig. 1 show the relationships between sclerostin and 
various parameters according to Pearson correlation analysis. 
Table 1. Baseline Clinical Characteristics of Premenopausal and Postmenopausal Women
Characteristic Premenopause (n=36) Postmenopause (n=90) P value
Age, yr 28.0±6.3 57.7±7.0 <0.001
BMI, kg/m2 21.2±3.1 24.3±3.1 <0.001
BMD L1–L4, g/cm2 0.985±0.1 0.918±0.1 0.002
BMD total hip, g/cm2 0.859±0.1 0.823±0.1 NS
Osteocalcin, ng/mL 12.6±3.2 22.0±9.0 <0.001
C-telopeptide, ng/mL 0.25±0.1 0.38±0.2 0.001
Serum calcium, mg/dL 9.4±0.4 9.2±0.4 0.015
Serum phosphorus, mg/dL 4.0±0.4 3.9±0.6 NS
Serum PTH, pg/mL 35.7±11.6 27.0±12.1 <0.001
25(OH)D, ng/mL 25.6±12.0 15.5±7.0 <0.001
Serum sclerostin, pmol/L 23.1±4.8 27.8±13.6 0.029
Values are expressed as mean±SD. P values determined by Student t test.
BMI, body mass index; BMD, bone mineral density; NS, not significant; PTH, parathyroid hormone; 25(OH)D, 25-hydroxyvitamin D.
Table 2. Partial Correlations between Sclerostin and Various 
Parameters in Premenopausal and Postmenopausal Women 
Adjusted for Body Mass Index
Parameter
Premenopause Postmenopause
ra P value ra P value
Weight 0.028 NS 0.220 0.047
Osteocalcin −0.218 NS 0.131 NS
C-telopeptide −0.031 NS −0.093 NS
Serum calcium −0.073 NS −0.084 NS
Serum phosphorus 0.028 NS 0.028 NS
Serum PTH −0.010 NS −0.088 NS
25(OH)D −0.062 NS 0.042 NS
P values calculated by Pearson correlation analysis. 
NS, not significant; PTH, parathyroid hormone; 25(OH)D, 25-hy-
droxyvitamin D.
ar, partial correlation coefficient adjusted for body mass index.
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Serum baseline sclerostin level positively correlated with lum-
bar spine and total hip BMD (r=0.218 and r=0.233; P<0.05, 
respectively) (Fig. 1), but only in the postmenopausal group. 
No significant correlations were observed between bone turn-
over markers such as CTx and OCN and serum sclerostin (Ta-
ble 2). A negative correlation was observed between PTH and 
sclerostin in postmenopausal women (r=–0.074), but was not 
significant. Serum calcium, phosphorus, and 25(OH)D had no 
relevant relationships with sclerostin levels.
Biochemical changes after AI treatment with or without 
alendronate
We further divided the postmenopausal patients into two sub-
groups based on medications: 5 mg alendronate and calcitriol 
in one group, and calcium and vitamin D only in the other 
group. Baseline characteristics were presented in a previous re-
port [2]. Baseline features, such as the period after menopause, 
biochemical parameters, and baseline BMD at all sites were 
similar between the two groups. Serum OCN and CTx levels 
increased significantly in both groups after 24 weeks of AI ad-
ministration, but increased lesser in the alendronate-treated 
group by 29.0% and 72.4%, respectively [2].
 We also analyzed percent changes in sclerostin levels from 
baseline to 24 weeks after AI use and found a significant in-
crease (48.1%±6.9%, P<0.05) in all postmenopausal women. 
Sclerostin levels in the placebo group increased significantly 
after 24 weeks of AI administration (55.9%±9.13%, P< 
0.001). Less of an increase was observed in patients treated 
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Fig. 1. Partial correlations between sclerostin, lumbar spine bone mineral density (BMD), and total hip BMD after adjusting for body 
mass index. (A, B) Premenopausal women. (C, D) Postmenopausal women. Circulating sclerostin positively correlated with lumbar 
spine and total hip BMD only in postmenopausal women (C, r=0.439, P<0.001; D, r=0.454, P<0.001, respectively). The age-adjusted 
correlation between BMD and sclerostin remained positive (data not shown). NS, not significant.
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with alendronate (39.9%±10.2%, P<0.001) (Fig. 2), but this 
was not significantly different from the increase in the placebo 
group.
 
DISCUSSION
We showed higher serum sclerostin levels in postmenopausal 
women compared to those in premenopausal women. Scleros-
tin was positively correlated with BMD in postmenopausal 
women at all sites. In addition, sclerostin levels increased fur-
ther after use of an AI which is a treatment for breast cancer 
that ablates the remnant estrogen, but were not affected by the 
use of alendronate.
 Sclerostin, encoded by the SOST gene, is a major Wnt antag-
onist and a potent inhibitor of bone formation [4]. Previous ani-
mal studies have shown that overexpression of the SOST gene 
causes osteopenia [5]. Moreover, production of sclerostin by 
osteocytes is dramatically reduced by mechanical loading in 
rodents [17-19]. Thus, sclerostin may be a potential specific 
marker for bone metabolism, but the clinical implications are 
not completely understood. Modder et al. [20] showed that 
sclerostin levels increase with age and are higher in men com-
pared to women. Polyzos et al. [21] reported that serum 
sclerostin is positively correlated with lumbar spine BMD and 
T-score. Arasu et al. [22] also found a positive correlation be-
tween sclerostin and BMD. A positive correlation was observed 
between serum sclerostin and spine and total hip BMD by Gar-
nero et al. [23], which was in accordance with our data. They 
also found negative correlations between sclerostin and CTx, 
serum intact N-terminal propeptide of type I collagen, and in-
tact PTH. However, the risk of hip fractures is higher in pa-
tients with a higher serum sclerostin level [22]. A strong asso-
ciation was observed between increased sclerostin levels and 
osteoporosis-related fracture risk in postmenopausal women 
[24]. The paradoxical positive correlation between sclerostin 
and BMD suggests that serum sclerostin may reflect the num-
ber of osteocytes rather than individual cell activity or individ-
ual bone remodeling units [25].
 The possible regulators of circulating sclerostin levels are 
known as such; increasing the level by mechanical unloading, 
immobilization, male sex, aging, and decreasing by mechani-
cal loading, exercise and PTH [17-24,26]. Among them, PTH 
is probably one of the most important regulators of sclerostin 
secretion in postmenopausal women [23]. Sclerostin is also af-
fected by estrogens. It is well established that estrogen defi-
ciency increases serum sclerostin levels and is associated with 
bone loss [27-29]. Modder et al. [7] reported that 4 weeks of 
estrogen treatment in postmenopausal women decreased se-
rum sclerostin levels. Endogenous estrogen and testosterone 
production were ablated in 59 elderly men by administering 
gonadotropin-releasing hormone, after which these patients 
were given physiological levels of testosterone and estrogen. 
As a result, estrogen, but not  testosterone, prevented an increase 
in sclerostin following induction of sex steroid deficiency [7]. 
Consistent with previous studies, our study also revealed a 
negative relationship between estrogen and sclerostin. The 
possible mechanism of how estrogen suppresses sclerostin 
production is that estrogen interacts with the Wnt/β-catenin 
signaling pathway, a main pathway of sclerostin action, by 
binding to the estrogen receptor via several factors such as 
prostaglandin E2 [9,25].
 In this study, subjects with endocrine-responsive breast can-
cer who were treated with an AI showed reduced remnant es-
trogens and bone mass [14-16], and showed elevated scleros-
tin levels. As mentioned above, estrogens and sclerostin have 
an inverse correlation [27-29]. In addition to this concept, our 
results revealed that further suppression of remnant estrogens 
sensitively affected serum sclerostin levels. Thus, we suggest 
that sclerostin may be a surrogate marker for quantitative and 
sensitive changes in estrogens and bone remodeling.
Fig. 2. Comparison of changes in sclerostin. Sclerostin was mea-
sured at baseline and after 24 weeks of aromatase inhibitor admin-
istration. We compared changes in sclerostin in the placebo and 
alendronate with calcitriol groups, and showed a significant in-
crease in sclerostin levels in both groups (placebo group, P<0.05; 
alendronate with calcitriol group, P<0.05, by paired t test). How-
ever, the changes in sclerostin levels in the groups were not sig-
nificantly different (P=not significant).
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 Polyzos et al. [21] reported that serum sclerostin increases 
significantly after 6 months of risedronate use. However, 
Chung et al. [30] found that circulating sclerostin levels were 
suppressed by raloxifene, but not by bisphosphonates. They 
suggested that sclerostin may mediate the action of estrogens 
on bone metabolism independently of the anti-resorptive ef-
fects. Our results revealed a significant increase in sclerostin 
levels after 24 weeks of AI administration, with a slightly 
blunted increase during alendronate treatment, but without 
statistical significance.
 This study had some limitations. We demonstrated differ-
ences in bone markers, BMD, and serum sclerostin levels be-
tween premenopausal and postmenopausal women. However, 
the results are difficult to generalize because of the small num-
ber of subjects.
 In conclusion, our data show that serum sclerostin levels 
positively correlated with BMD at all sites, and that serum 
sclerostin increased according to the level of estrogen defi-
ciency in postmenopausal women, and was further increased 
by AI treatment. Additional experimental and clinical studies 
in a larger population and with other drugs that correlate with 
sclerostin are needed.
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